Sol-Gel Technologies (SLGL) EBITDA (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly EBITDA of $3.9 million for Q1 2026, down 57.49% year-over-year from $9.1 million in Q1 2025, and up 213.02% quarter-over-quarter from -$3.4 million in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) EBITDA (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported EBITDA for 10 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 57.49% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $5.4 million (up 43.02% YoY), while the FY2025 annual figure was -$7.5 million, up 37.26% from the prior year.
- EBITDA advanced to $3.9 million in Q1 2026 per SLGL's latest filing, from -$3.4 million in the prior quarter.
- Across five years, EBITDA topped out at $11.2 million in Q2 2025 and bottomed at -$6.5 million in Q2 2023.
- Historically, EBITDA has averaged $309941.2 across 5 years, with a median of -$828000.0 in 2024.
- Annual changes were most pronounced in 2023 — EBITDA plunged 1509.72% — and 2025, when it surged 591.5%.
- Sol-Gel Technologies' EBITDA stood at -$6.2 million in 2022, then climbed by 12.86% to -$5.4 million in 2023, then declined by 12.8% to -$6.1 million in 2024, then soared by 44.07% to -$3.4 million in 2025, then jumped by 213.02% to $3.9 million in 2026.
- Business Quant data shows SLGL's EBITDA at $3.9 million in Q1 2026, -$3.4 million in Q4 2025, and -$6.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -4.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.16 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 11.23 Mn |
| Mar 31, 2025 | 9.07 Mn |
| Dec 31, 2024 | -6.10 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | -5.41 Mn |
| Sep 30, 2023 | -6.31 Mn |
| Jun 30, 2023 | -6.53 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 463,000.00 |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 13.96 Mn |
| Sep 30, 2021 | 1.27 Mn |